Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/KCNMA1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/KCNMA1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/KCNMA1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/KCNMA1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/KCNMA1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/KCNMA1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/KCNMA1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/KCNMA1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001003820 | Oral cavity | OSCC | response to metal ion | 188/7305 | 373/18723 | 4.34e-06 | 5.00e-05 | 188 |
GO:00069706 | Oral cavity | OSCC | response to osmotic stress | 50/7305 | 84/18723 | 1.11e-04 | 8.15e-04 | 50 |
GO:00083618 | Oral cavity | OSCC | regulation of cell size | 92/7305 | 181/18723 | 7.86e-04 | 4.26e-03 | 92 |
GO:007048226 | Skin | cSCC | response to oxygen levels | 133/4864 | 347/18723 | 2.39e-07 | 5.07e-06 | 133 |
GO:000166626 | Skin | cSCC | response to hypoxia | 116/4864 | 307/18723 | 3.09e-06 | 4.81e-05 | 116 |
GO:003629326 | Skin | cSCC | response to decreased oxygen levels | 119/4864 | 322/18723 | 7.98e-06 | 1.09e-04 | 119 |
GO:001003829 | Skin | cSCC | response to metal ion | 132/4864 | 373/18723 | 3.11e-05 | 3.42e-04 | 132 |
GO:0032535111 | Skin | cSCC | regulation of cellular component size | 131/4864 | 383/18723 | 1.89e-04 | 1.59e-03 | 131 |
GO:000697021 | Skin | cSCC | response to osmotic stress | 35/4864 | 84/18723 | 1.23e-03 | 7.97e-03 | 35 |
GO:005159217 | Skin | cSCC | response to calcium ion | 52/4864 | 149/18723 | 9.63e-03 | 4.31e-02 | 52 |
GO:007048228 | Thyroid | ATC | response to oxygen levels | 193/6293 | 347/18723 | 1.83e-17 | 1.93e-15 | 193 |
GO:003629328 | Thyroid | ATC | response to decreased oxygen levels | 177/6293 | 322/18723 | 1.81e-15 | 1.32e-13 | 177 |
GO:000166628 | Thyroid | ATC | response to hypoxia | 169/6293 | 307/18723 | 6.58e-15 | 4.12e-13 | 169 |
GO:003253526 | Thyroid | ATC | regulation of cellular component size | 191/6293 | 383/18723 | 2.51e-11 | 8.69e-10 | 191 |
GO:000836122 | Thyroid | ATC | regulation of cell size | 89/6293 | 181/18723 | 1.01e-05 | 1.00e-04 | 89 |
GO:0010038210 | Thyroid | ATC | response to metal ion | 165/6293 | 373/18723 | 1.07e-05 | 1.05e-04 | 165 |
GO:000697016 | Thyroid | ATC | response to osmotic stress | 45/6293 | 84/18723 | 1.27e-04 | 9.03e-04 | 45 |
GO:005159225 | Thyroid | ATC | response to calcium ion | 69/6293 | 149/18723 | 8.43e-04 | 4.62e-03 | 69 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KCNMA1 | SNV | Missense_Mutation | | c.3332C>T | p.Ala1111Val | p.A1111V | Q12791 | protein_coding | deleterious(0.04) | possibly_damaging(0.877) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
KCNMA1 | SNV | Missense_Mutation | novel | c.793N>C | p.Asn265His | p.N265H | Q12791 | protein_coding | tolerated(0.12) | benign(0.014) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KCNMA1 | SNV | Missense_Mutation | | c.1585N>T | p.His529Tyr | p.H529Y | Q12791 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
KCNMA1 | SNV | Missense_Mutation | novel | c.3481N>T | p.Ile1161Phe | p.I1161F | | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.958) | TCGA-C8-A27A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
KCNMA1 | SNV | Missense_Mutation | novel | c.3335A>G | p.Asp1112Gly | p.D1112G | Q12791 | protein_coding | tolerated(0.21) | benign(0) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
KCNMA1 | SNV | Missense_Mutation | | c.2832C>G | p.Ile944Met | p.I944M | Q12791 | protein_coding | deleterious(0) | probably_damaging(0.933) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
KCNMA1 | SNV | Missense_Mutation | | c.1613N>G | p.Pro538Arg | p.P538R | Q12791 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A14R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
KCNMA1 | SNV | Missense_Mutation | | c.2714N>A | p.Thr905Lys | p.T905K | Q12791 | protein_coding | deleterious(0) | possibly_damaging(0.545) | TCGA-EW-A3U0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
KCNMA1 | SNV | Missense_Mutation | novel | c.2186N>A | p.Arg729His | p.R729H | Q12791 | protein_coding | tolerated(0.37) | benign(0) | TCGA-LL-A5YL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
KCNMA1 | SNV | Missense_Mutation | novel | c.2059N>G | p.Pro687Ala | p.P687A | Q12791 | protein_coding | tolerated(0.13) | benign(0.242) | TCGA-LL-A6FP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3778 | KCNMA1 | DRUGGABLE GENOME, ION CHANNEL | activator | CHEMBL119549 | ANDOLAST | |
3778 | KCNMA1 | DRUGGABLE GENOME, ION CHANNEL | blocker | 178101035 | | |
3778 | KCNMA1 | DRUGGABLE GENOME, ION CHANNEL | activator | 178101089 | CHEMBL1290115 | |
3778 | KCNMA1 | DRUGGABLE GENOME, ION CHANNEL | activator | 135651381 | | |
3778 | KCNMA1 | DRUGGABLE GENOME, ION CHANNEL | | CHLORZOXAZONE | CHLORZOXAZONE | |
3778 | KCNMA1 | DRUGGABLE GENOME, ION CHANNEL | activator | 178101088 | | |
3778 | KCNMA1 | DRUGGABLE GENOME, ION CHANNEL | activator | 135650743 | | |
3778 | KCNMA1 | DRUGGABLE GENOME, ION CHANNEL | | TRICHLORMETHIAZIDE | TRICHLORMETHIAZIDE | |
3778 | KCNMA1 | DRUGGABLE GENOME, ION CHANNEL | | ENFLURANE | ENFLURANE | |
3778 | KCNMA1 | DRUGGABLE GENOME, ION CHANNEL | blocker | 135651249 | | |